Pinsent Masons Guides Redx In $880M Cancer Drug Sale
By Dawood Fakhir · February 7, 2024, 4:28 PM GMT
Biotechnology company Redx Pharma PLC on Wednesday said that it has agreed to sell global rights for further development of a cancer-fighting program to Jazz Pharmaceuticals PLC for up to $880...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login